Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial

BACKGROUND: Early detection and treatment of asymptomatic men with advanced and high-risk prostate cancer (PCa) may improve survival rates. OBJECTIVE: To determine outcomes for men diagnosed with advanced PCa following prostate-specific antigen (PSA) testing who were excluded from the ProtecT random...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Eur Urol
Auteurs principaux: Johnston, Thomas J., Shaw, Greg L., Lamb, Alastair D., Parashar, Deepak, Greenberg, David, Xiong, Tengbin, Edwards, Alison L., Gnanapragasam, Vincent, Holding, Peter, Herbert, Phillipa, Davis, Michael, Mizielinsk, Elizabeth, Lane, J. Athene, Oxley, Jon, Robinson, Mary, Mason, Malcolm, Staffurth, John, Bollina, Prasad, Catto, James, Doble, Andrew, Doherty, Alan, Gillatt, David, Kockelbergh, Roger, Kynaston, Howard, Prescott, Steve, Paul, Alan, Powell, Philip, Rosario, Derek, Rowe, Edward, Donovan, Jenny L., Hamdy, Freddie C., Neal, David E.
Format: Artigo
Langue:Inglês
Publié: Elsevier Science 2017
Sujets:
Platinum Priority – Prostate Cancer
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5289293/
https://ncbi.nlm.nih.gov/pubmed/27720537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2016.09.040
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires